Inhibition of Ca2+-calmodulin dependent phosphodiesterase (PDE1B1)

By Epstein P.M.  

Expert Opinion on Therapeutic Targets, Vol. 2, Iss. 1, 1998-07 ,pp. : 109-112

Informa Healthcare

Access to resources Recommend Favorite

Discriminative effects of CGS 15943, a competitive adenosine receptor antagonist, have a dopamine component in monkeys

By Holtzman S.G.  

European Journal of Pharmacology, Vol. 376, Iss. 1, 1999-07 ,pp. : 7-15

Elsevier

Access to resources Recommend Favorite

Calmodulin kinase II as a target for inhibition in cardiac disease

By Doggrell Sheila A  

Expert Opinion on Therapeutic Targets, Vol. 9, Iss. 6, 2005-12 ,pp. : 1319-1321

Informa Healthcare

Access to resources Recommend Favorite

The use of adjuvant radiotherapy in elderly patients with early-stage breast cancer: Changes in practice patterns after publication of Cancer and Leukemia Group B 9343

By Palta Manisha   Palta Priya   Bhavsar Nrupen A.   Horton Janet K.   Blitzblau Rachel C.  

Cancer, Vol. 121, Iss. 2, 2015-01 ,pp. : 188-193

Blackwell Publishing

Access to resources Recommend Favorite

DY-9760e, a novel calmodulin antagonist with cytoprotective action

By Sugimura M.   Sato T.   Nakayama W.   Morishima Y.   Fukunaga K.   Omitsu M.   Miyamoto E.   Shirasaki Y.  

European Journal of Pharmacology, Vol. 336, Iss. 1, 1997-10 ,pp. : 99-106

Elsevier

Access to resources Recommend Favorite